Participating Faculty: Expenditures for Medicaid Patients Treated With Exenatide Compared With Other Diabetes Management Regimens

The American Journal of Managed Care

This supplement to reports results from a retrospective cohort analysis of Medicaid claims data designed to compare Medicaid spending among patients with type 2 diabetes mellitus receiving exenatide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, or basal insulin as add-on antidiabetic therapy. It also discusses the implications and limitations of these study results.This supplement was supported by Amylin Pharmaceuticals, Inc.

FacultyJennie H. Best, PhD

Director, Health Economics and Outcomes Research

Medical Research and Development

Amylin Pharmaceuticals, Inc

San Diego, California

Ryan M. Conrad, PhD

Economist

Precision Health Economics, LLC

Los Angeles, California

Dana P. Goldman, PhD

Norman Topping Chair in Medicine and Public Policy

Price School of Public Policy

Director

Leonard D. Schaeffer Center for Health Policy and Economics

University of Southern California

Los Angeles, California

Anne L. Peters, MD

Professor

Division of Endocrinology

Keck School of Medicine

Director

Clinical Diabetes Program

University of Southern California

Los Angeles, California

John A. Romley, PhD

Research Assistant Professor

Price School of Public Policy

University of Southern California

Los Angeles, California

Disclosures

These faculty report relationships with the following organizations:

Jennie H. Best, PhD

Employee and stock ownership: Amylin Pharmaceuticals, Inc

Ryan M. Conrad, PhD

Consultant: Amylin Pharmaceuticals, Inc

Dana P. Goldman, PhD

Consultant: Amylin Pharmaceuticals, Inc

Anne L. Peters, MD

Consultant: Amylin Pharmaceuticals, Inc, Boehringer Ingelheim, CellNovo, Lilly, Novo Nordisk, sanofi-aventis

Honoraria: Dexcom, Medtronic MiniMed, Merck, Medscape, Perrigo

Speakers’ bureau: Amylin Pharmaceuticals, Inc, Takeda, Lilly, Novo Nordisk

John A. Romley, PhD

Consultant: Amylin Pharmaceuticals, Inc

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Download PDF: Participating Faculty: Expenditures for Medicaid Patients Treated With Exenatide Compared With Other Diabetes Management Regimens